therapeutics News and Research

RSS

New Framework Uses Genetic Variant Data to Recall Biobank Participants

Clinical biobanks that combine genomic data with electronic health records (EHRs) have become powerful resources for discovering genetic variants associated with disease.

28 Jul 2026

Novel Dendritic Cell Vaccine Redirects Viral Memory to Fight Tumors

In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history

28 Jul 2026

Elevated Levels of Acid Ceramidase Make Zombie Cells Susceptible to Ferroptosis

Our population is aging. The United Nations reports that by 2050, the number of people over the age of 85 on our planet is set to triple.

24 Jul 2026

Study Reveals How Genome Regulation Changes During Brain Aging

Researchers have discovered that the human brain undergoes widespread age-related changes in genome regulation beginning in midlife that may help explain why aging is the greatest risk factor for neurodegenerative diseases such as Alzheimer's.

24 Jul 2026

Researchers Find New Bacterial Mechanism for Evading Antibiotic Exposure

Antibiotics are a medical marvel, but many microbes are gaining the ability to resist and tolerate these therapeutics.

24 Jul 2026

Changes in RNA Regulation Enable Bacteria to Enter Antibiotic Tolerance

Antibiotics are a medical marvel, but many microbes are gaining the ability to resist and tolerate these therapeutics. St. Jude Children's Research Hospital scientists have uncovered how S. pneumoniae adapts to antibiotic exposure and immune pressures.

23 Jul 2026

New Open Source AI Toolkit Identifies Promising Peptide Medicines

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

22 Jul 2026

Demographic Biases Threaten the Fairness of Global Single-Cell Human Atlases

The single-cell "atlases" that are increasingly used to map the human body and as training data for artificial intelligence models, may not represent the world's populations fairly, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai.

21 Jul 2026

Innovative Bioelectronic Ear Devices Offer New Hope for Asthma Relief

Neuroimmunology, the study of interactions between the nervous and immune systems, is a rapidly growing field enabling new approaches for monitoring and treating inflammatory diseases.

16 Jul 2026

New CRISPR Atlas Details How Every Gene Influences Stem Cells

A team led by bioengineers at the University of California San Diego has developed a genome-scale reference map that details how individual genes control the functions and identities of human stem cells.

14 Jul 2026

Global Breakthrough Maps Genes and Cells Regulating Bone Health

In a global breakthrough published in Nature Genetics, researchers have successfully mapped the cells and genes that regulate bone formation and loss at an unprecedented scale and discovered the critical role that blood vessel cells play in bone health.

11 Jul 2026

Single Experiment Tool Allows Researchers to Test Thousands of Proteins

To prevent viruses from sickening or killing us - whether it's an individual case of hepatitis B or a COVID pandemic - it's crucial to understand how the proteins they make initiate changes in our bodies that allow them to flourish.

11 Jul 2026

Advanced Synthetic Bone Graft Fights Infections and Kills Cancer Cells

Primary bone tumors, such as osteosarcoma, have seen stagnant survival rates over the past four decades.

10 Jul 2026

Which Molecular Data Types Help AI Predict Drugs Best?

This study reveals that late fusion of diverse molecular representations significantly boosts drug discovery model accuracy, optimizing prediction strategies.

9 Jul 2026

Gut Microbiome Signatures Correlate With Clinical Efficacy in Immunotherapy Outcomes

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

9 Jul 2026

New Aptamer Selection Strategy Streamlines Development of Safer Therapeutic Candidates

G protein-coupled receptors (GPCRs) are the most abundantly expressed proteins in the human body, which regulate diverse physiological processes ranging from pain perception to hormone signaling.

8 Jul 2026

Research Links Evolved Long Noncoding RNAs to Cancer Growth

In cancer research, one person's junk is increasingly becoming another person's treasure. Scientists have now uncovered new evidence showing how recently evolved "junk DNA" genetic elements can become integrated into ancient cellular pathways that regulate cancer.

2 Jul 2026

University of Utah Study Identifies Arc Protein as Alzheimer's Driver

Alzheimer's disease is driven by a buildup of a toxic protein called Tau that kills neurons. As toxic Tau spreads to new regions of the brain, symptoms become worse and ultimately fatal.

30 Jun 2026

Researchers Develop Non-Toxic Way to Generate the Symptoms of Parkinson's Disease

Scientists usually use animal models when studying Parkinson's disease because these models mimic the disease well.

30 Jun 2026

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price.

From Bio-Techne 26 Jun 2026